Innovative therapeutics

Investors

NASDAQBMRN
FormDescriptionDateFormat
4Statement of changes in beneficial ownership of securitiesFeb 19, 2014View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesFeb 19, 2014View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesFeb 19, 2014View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesFeb 19, 2014View HTMLDownload DOCDownload PDF
5Annual filing director officer or owner of more than ten percent.Feb 14, 2014View HTMLDownload DOCDownload PDF
5Annual filing director officer or owner of more than ten percent.Feb 14, 2014View HTMLDownload DOCDownload PDF
5Annual filing director officer or owner of more than ten percent.Feb 14, 2014View HTMLDownload DOCDownload PDF
5Annual filing director officer or owner of more than ten percent.Feb 13, 2014View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesFeb 7, 2014View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesFeb 4, 2014View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJan 14, 2014View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJan 8, 2014View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJan 6, 2014View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJan 6, 2014View HTMLDownload DOCDownload PDF
1-25      26-50      51-75      76-89

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq™
Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information